Insider trades
Open-market buys and sales that US company officers, directors and 10% owners file, newest filing first.
| Trade type | ||||||||
|---|---|---|---|---|---|---|---|---|
Arcutis BiotherapeuticsARQT | Open-market sale10b5-1 plan | 06/15–06/17 | 06/17 | 4,731 sh2 trades | $24.58avg. | $116,283.81 | −11.1% | |
Sue-Jean LinDirector | Arcutis BiotherapeuticsARQT | Open-market sale10b5-1 plan | 06/15 | 06/17 | 4,946 sh | $24.38 | $120,583.48 | −15.2% |
Burnett PatrickSEE REMARKS | Arcutis BiotherapeuticsARQT | Open-market sale10b5-1 plan | 05/11 | 05/13 | 222 sh | $21.05 | $4,673.1 | −0.2% |
Latha VairavanSVP CFO | Arcutis BiotherapeuticsARQT | Open-market sale10b5-1 plan | 05/11 | 05/13 | 435 sh | $21.05 | $9,156.75 | −0.5% |
Burnett PatrickSEE REMARKS | Arcutis BiotherapeuticsARQT | Open-market sale10b5-1 plan | 05/04 | 05/06 | 684 sh | $23.61 | $16,149.24 | −0.6% |
Arcutis BiotherapeuticsARQT | Open-market sale10b5-1 plan | 05/04 | 05/06 | 8,256 sh2 trades | $23.31avg. | $192,417.68 | −6.1% | |
Todd WatanabeSEE REMARKS | Arcutis BiotherapeuticsARQT | Open-market sale10b5-1 plan | 05/04 | 05/06 | 3,172 sh | $23.61 | $74,890.92 | −0.4% |
Latha VairavanSVP CFO | Arcutis BiotherapeuticsARQT | Open-market sale10b5-1 plan | 05/04 | 05/06 | 1,341 sh | $23.61 | $31,661.01 | −1.5% |
Welgus Howard G.Director | Arcutis BiotherapeuticsARQT | Open-market sale10b5-1 plan | 05/01 | 05/05 | 7,144 sh | $22.99 | $164,240.56 | −18.0% |
Welgus Howard G.Director | Arcutis BiotherapeuticsARQT | Open-market sale10b5-1 plan | 04/01 | 04/03 | 10,000 sh | $23.88 | $238,800 | −20.1% |
Keith R. LeonardDirector | Arcutis BiotherapeuticsARQT | Open-market sale10b5-1 plan | 03/02 | 03/04 | 39,272 sh | $25.39 | $997,116.08 | −64.0% |
Welgus Howard G.Director | Arcutis BiotherapeuticsARQT | Open-market sale10b5-1 plan | 03/02 | 03/04 | 10,000 sh | $25.65 | $256,500 | −16.7% |
Arcutis BiotherapeuticsARQT | Open-market sale10b5-1 plan | 03/02 | 03/03 | 6,287 sh2 trades | $25.18avg. | $158,316.67 | −4.9% | |
Arcutis BiotherapeuticsARQT | Open-market sale10b5-1 plan | 02/27–03/02 | 03/03 | 12,058 sh4 trades | $26.03avg. | $313,873.76 | −8.1% | |
Arcutis BiotherapeuticsARQT | Open-market sale10b5-1 plan | 03/02 | 03/03 | 37,349 sh2 trades | $25.18avg. | $940,501.84 | −4.5% | |
Arcutis BiotherapeuticsARQT | Open-market sale10b5-1 plan | 03/02 | 03/03 | 3,687 sh2 trades | $25.18avg. | $92,842.17 | −2.1% | |
Arcutis BiotherapeuticsARQT | Open-market sale10b5-1 plan | 03/02 | 03/03 | 2,853 sh2 trades | $25.18avg. | $71,842.23 | −3.1% | |
Arcutis BiotherapeuticsARQT | Open-market sale10b5-1 plan | 02/02–02/04 | 02/04 | 13,469 sh2 trades | $25.73avg. | $346,495.64 | −14.3% | |
Arcutis BiotherapeuticsARQT | Open-market sale10b5-1 plan | 02/02 | 02/04 | 40,638 sh4 trades | $25.28avg. | $1,027,305.42 | −27.0% | |
Welgus Howard G.Director | Arcutis BiotherapeuticsARQT | Open-market sale10b5-1 plan | 02/02 | 02/04 | 10,000 sh | $25.05 | $250,500 | −14.3% |